Iqirvo® (elafibranor)

Iqirvo is an oral, once-daily, peroxisome proliferator-activated receptor alpha/delta (PPAR α/δ) agonist approved for primary biliary cholangitis (PBC). Activation of PPARα inhibits molecules that promote inflammation, it decreases bile toxicity and mitigates oxidative stress. PPARδ enhances bile flow, energy metabolism and anti-fibrotic pathways. The dual activation of PPAR-α and PPAR-δ works synergistically to address cholestasis, inflammation, and fibrosis in PBC. Iqirvo has been granted accelerated approval in the US and conditional approval in EU for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.